No Data
No Data
Leerink Partners Initiates Shattuck Labs(STTK.US) With Buy Rating, Announces Target Price $4
Leerink Partners Initiates Shattuck Labs at Outperform With $4 Price Target
Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock
Shattuck Labs' SL-325 Shows Positive Results in Inflammatory Bowel Disease
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn's and Colitis Congress
Stocks Mostly Rise Pre-Bell Ahead of Key Jobs Data; Asia, Europe Strong